Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:XCUR

Exicure Earnings Date & Estimates

Exicure logo
$1.12 0.00 (0.00%)
Closing price 10/16/2026 03:59 PM Eastern
Extended Trading
$1.15 +0.03 (+3.04%)
As of 10/16/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exicure is estimated to report earnings on Thursday, November 12, 2026.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Exicure

Exicure is expected to post earnings of -$18.60 per share on revenue of $1.64 million. In the same quarter a year earlier Exicure reported -$0.39 per share. Exicure last reported on August 14, 2026, posting -$0.18 per share and beating the -$18.60 consensus estimate.

Consensus Estimates

Consensus EPS
-$18.60
Expected Revenue
$1.64 million
Prior-Year EPS
-$0.39

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.18 (Beat by +$18.42)

Prepare for the Earnings Call

Exicure Earnings FAQ

Exicure (NASDAQ:XCUR) is estimated to report earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Exicure to post earnings of -$18.60 per share for the quarter.

The consensus revenue estimate for Exicure is $1.64 million for the quarter.

Exicure Earnings Headlines

Exicure Granted Extension By Nasdaq To Regain Compliance By Dec. '26
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691538/exicure-granted-extension-by-nasdaq-to-regain-compliance-by-dec-26.aspx
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/exicure-receives-nasdaq-extension-regain-120000361.html
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
October 17 at 1:00 AM  |  Stansberry Research (Ad)
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363130/33289/en/exicure-receives-nasdaq-extension-to-regain-compliance-with-stockholders-equity-requirement.html
Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics
August 3, 2026  |  quiverquant.comQ
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337599/33289/en/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance.html
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR) is a biotechnology company that historically focused on developing nucleic acid-based medicines. Its research was built around Spherical Nucleic Acid (SNA) technology, a platform designed to package and deliver short strands of genetic material into cells to influence disease-related biological pathways.

The company’s development programs included investigational treatments for oncology, inflammatory diseases and genetic disorders. Its most prominent candidates included cavrotolimod, an immunotherapy designed to activate the toll-like receptor 9 pathway, and earlier dermatology-focused programs intended to address conditions such as psoriasis and related inflammatory diseases. These candidates were investigational and were not established commercial products.

Exicure was founded in 2011 and was based in the Chicago area. The company entered into research and development collaborations with pharmaceutical partners, including AbbVie, to explore applications of its SNA technology. Public disclosures in subsequent years indicated significant operational and corporate challenges, and information about its ongoing programs, leadership and commercial activities has been limited.

View Exicure Profile
Earnings Tools